Today: 21 May 2026
Tesla stock drops as Musk’s $20 billion robotaxi spending push takes over
29 January 2026
2 mins read

Tesla stock drops as Musk’s $20 billion robotaxi spending push takes over

New York, Jan 29, 2026, 16:04 EST — After-hours

  • Tesla shares dropped roughly 3.7% during regular trading, reversing an initial spike
  • Company set 2026 capital spending to exceed $20 billion, focused on robotaxis and robots
  • Investors are focusing on timelines, cash burn, and regulatory challenges surrounding “no wheel, no pedals” vehicles

Tesla shares fell on Thursday following an initial surge, as investors digested the company’s deeper push into autonomy and robotics—and the higher costs that come with it. The stock dropped 3.7% to $415.6 by the close, having fluctuated between $445.1 and $415.0 during the day.

This move is significant as Tesla’s narrative is evolving once more, with the market scrambling to adjust its valuation on the fly. While car sales continue, much of the company’s high valuation depends on its ability to build a scalable business around self-driving software and a robotaxi network.

The near-term question for traders is straightforward: how much spending will it take to reach those targets, and how quickly will the milestones come? At the moment, investors seem less focused on a straightforward “deliveries beat/miss” narrative and more on factory expansions, compute capacity, and regulatory advances.

Tesla’s latest quarterly update highlighted a mixed bag. Fourth-quarter revenue slipped 3% to $24.9 billion, while net income tied to shareholders plunged 61% to $840 million. On the upside, energy generation and storage revenue climbed 25% to $3.84 billion. The company reported delivering 418,227 vehicles during the quarter and closed 2025 with $44.1 billion in cash and investments. Active subscriptions to its Full Self-Driving (Supervised) package grew to 1.1 million.

During the earnings call, Tesla revealed a $2 billion stake in Elon Musk’s AI venture xAI and confirmed that Cybercab production remains scheduled for this year. Thomas Monteiro, senior analyst at Investing.com, noted that the shift focuses investors more on “rollout metrics — not deliveries” when it comes to the stock. Reuters

The spending plan shook the market on Thursday. Tesla intends to more than double its capital expenditures, pushing them past $20 billion in 2026. Most of that budget will fund production lines for the Cybercab, Optimus humanoid robots, the long-awaited Semi truck, and battery and lithium projects, Reuters reported. Scott Acheychek, COO at REX Financial, called it “the business model transition now underway,” while Zacks strategist Andrew Rocco labeled the spending as “necessary.” Reuters

The downside is straightforward. Higher capital spending could tighten free cash flow, and robotaxis face regulatory hurdles—especially around Musk’s Cybercab design, which lacks a steering wheel and pedals. Meanwhile, fierce EV competition continues to weigh on prices.

Some investors fret Tesla is spreading itself too thin—juggling autonomy, robots, batteries, and now a formal tie to xAI. Musk has a history of missing self-driving deadlines, and a delayed timeline would force Tesla to rely more heavily on its car division just as competitors launch fresh models.

Traders are digging deeper than the earnings headline. Tesla filed its annual report and an 8-K on Wednesday, documents that often reveal extra details on funding, risks, and related-party transactions that could shift sentiment post-call.

Investors will be keeping an eye on Tesla to see if it holds steady in Friday’s trading, as analysts adjust their forecasts to reflect the updated capex baseline. Meanwhile, U.S. producer price data drops at 8:30 a.m. ET on Jan. 30. That report could move rate-sensitive growth stocks such as Tesla, depending on how it affects interest rate expectations.

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
SoFi stock slides ahead of Friday earnings as options price in a big SOFI move
Previous Story

SoFi stock slides ahead of Friday earnings as options price in a big SOFI move

Advanced Micro Devices (AMD) stock price holds near $252 after hours as AI spending jitters set up Feb. 3 earnings
Next Story

Advanced Micro Devices (AMD) stock price holds near $252 after hours as AI spending jitters set up Feb. 3 earnings

Go toTop